Clinical Trial Update: Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC [Phase 4]

View source ↗

Summary

A Phase 4 PALM-007 study in the Democratic Republic of Congo assessed the safety of the MVA-BN vaccine for monkeypox; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monkeypox

Drugs mentioned

• MVA-BN vaccine (Modified Vaccinia Ankara-Bavarian Nordic vaccine (MVA-BN))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Monkeypox | Phase 4 | Status: COMPLETED | Results posted: 2026-02-12